Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Xaluritamig - Amgen/Xencor

Next Previous
Drug Profile

Xaluritamig - Amgen/Xencor

Alternative Names: AMG-509

Latest Information Update: 03 Sep 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Amgen; Xencor
  • Developer Amgen; BeOne Medicines; Xencor
  • Class Antineoplastics; Bispecific antibodies; Immunoglobulin Fc fragments; Immunotherapies; Recombinant fusion proteins
  • Mechanism of Action Cytotoxic T lymphocyte stimulants; Immunologic cytotoxicity
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Ewing's sarcoma; Prostate cancer

Most Recent Events

  • 03 Sep 2026 Phase-III clinical trials in Ewing's Sarcoma (unspecified route) (Xencor pipeline, September 2026)
  • 29 May 2026 Efficacy and adverse events data from a phase I trial in Prostate cancer presented at the 62nd Annual Meeting of the American Society of Clinical Oncology (ASCO-2026)
  • 28 Apr 2026 Amgen initiates enrolment in the phase Ib trial for Prostate cancer (Metastatic disease, Hormone refractory, second line therapy or greater) in USA (IV) (NCT07493512)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top